Evidence map›Paper›PMID 34626792›Full record

ReviewCritical reviews in oncology/hematology2021

Severe acute respiratory syndrome coronavirus 2 infection in patients with prostate cancer: A critical review.

Orazio Caffo, Marco Messina, Antonello Veccia, Stefania Kinspergher, Francesca Maines, Carlo Messina

Open access · greenAbstract readReview
In one paragraph

Review in Critical reviews in oncology/hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Orazio CaffoMedical OncologyDepartments of Santa Chiara Hospital, Trento, Italy. Electronic address: orazio.caffo@apss.tn.it.
Marco MessinaMedical Oncology Departments of Civic Hospital, Palermo, Italy.
Antonello VecciaMedical OncologyDepartments of Santa Chiara Hospital, Trento, Italy.
Stefania KinspergherMedical OncologyDepartments of Santa Chiara Hospital, Trento, Italy.
Francesca MainesMedical OncologyDepartments of Santa Chiara Hospital, Trento, Italy.
Carlo MessinaMedical Oncology Departments of Civic Hospital, Palermo, Italy.
Ospedale Santa Chiara · ITUniversity of Palermo · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Real-world data suggest a possible interplay between androgen deprivation therapy (ADT) and susceptibility to and the severity of SARS-CoV-2 infection. As ADT is the backbone of prostate cancer treatment, various authors have evaluated different patient cohorts but the evidence provided is conflicting. The aim of this review is to assess the available publications concerning the role of ADT in preventing or reducing the severity of SARS-CoV-2 infection. After a literature search we identified four full papers, five letters, and four meeting abstracts, but these used different search methods and the quality of the evidence varied. They frequently had different endpoints, did not report the status of the prostate cancer patients and evaluated heterogeneous populations. The available data do not support the view that ADT protects against SARS-CoV-2 infection. Larger and more precise studies are warranted, considering variables that affect infection outcomes as these significantly influence the reliability of the findings.

Indexed as

COVID-19Prostatic NeoplasmsAndrogen AntagonistsHumansMaleReproducibility of ResultsSARS-CoV-2Androgen AntagonistsAndrogen deprivation therapyProstate cancerSARS-CoV-2

Identifiers

PMID34626792
PMCPMC8492888
OpenAlexW3205865700

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.